Julie Kim to Lead Takeda as Next CEO

Portfolio - People | Jan 30, 2025 | EIN

Julie Kim to Lead Takeda as Next CEO

Takeda's Board of Directors has announced Julie Kim as the successor to current CEO Christophe Weber, effective June 2026. Weber, recognized for transforming Takeda into a global R&D-driven biopharmaceutical player, will support Kim during a transition period over the next 18 months. The decision follows a rigorous multi-year succession process led by Masami Iijima, the chair of the Board and Nomination Committee. Kim, lauded for her leadership within the company and her previous role leading the U.S. and Plasma-Derived Therapies Business Unit, expressed her honor to lead Takeda through its next growth phase. The transition aligns with Takeda's strategic outlook, including new product launches and changes in the board of directors.

Sectors

  • Biopharmaceuticals
  • Corporate Governance

Geography

  • Japan – Takeda is headquartered in Japan, making it relevant to the geography of the article.
  • Global – Takeda's operations and leadership transition have global implications for the biopharmaceutical industry.

Industry

  • Biopharmaceuticals – The article discusses Takeda, a major player in the global biopharmaceutical industry, known for its R&D-driven approach.
  • Corporate Governance – The focus on leadership succession planning and board-level decision-making highlights corporate governance practices.

Financials

    Participants

    NameRoleTypeDescription
    Julie KimIncoming CEOPeopleJulie Kim has been chosen to succeed Christophe Weber as the CEO of Takeda in June 2026.
    Christophe WeberCurrent CEOPeopleCurrent CEO who transformed Takeda into a global biopharmaceutical company.
    Masami IijimaChair of the BoardPeopleChair of the Board and Nomination Committee at Takeda.
    Takeda PharmaceuticalsCompanyCompanyA major global biopharmaceutical company undergoing a CEO transition.